Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 24, 2026, 5:52 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Group 2 Placebo Clear all
Active, not recruiting Phase 2Phase 3 Interventional Results available

A Study of Guselkumab in Participants With Moderately to Severely Active Ulcerative Colitis

NCT04033445
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Placebo, Guselkumab
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
1,064 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
52
States / cities
Lancaster, California • Los Angeles, California • Colorado Springs, Colorado + 42 more
Source: ClinicalTrials.gov public record
Updated Aug 30, 2026 · Synced Sep 24, 2026, 5:52 PM EDT
Terminated Phase 2 Interventional

Efficacy and Safety Study of 4975 in Patients Undergoing Total Hip Replacement

NCT00683267
View directory record Official record
Conditions
Arthroplasty
Interventions
4975, highly purified capsaicin, Placebo
Drug
Lead sponsor
Anesiva, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
10
States / cities
Birmingham, Alabama • Arcadia, California • Glendale, California + 7 more
Source: ClinicalTrials.gov public record
Updated May 3, 2009 · Synced Sep 24, 2026, 5:52 PM EDT
Completed Phase 3 Interventional

Evaluation of Clinical Endpoints of Two Diclofenac Sodium Gel 1%

NCT01456611
View directory record Official record
Conditions
Osteo Arthritis of the Knee
Interventions
Diclofenac, Placebo
Drug
Lead sponsor
Anchen Pharmaceuticals, Inc
Industry
Eligibility
35 Years and older
Enrollment
749 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
57
States / cities
Birmingham, Alabama • Huntsville, Alabama • Chandler, Arizona + 54 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2012 · Synced Sep 24, 2026, 5:52 PM EDT
Completed Phase 2 Interventional

Efficacy and Safety of ALT-801 in the Treatment of Obesity

NCT05295875
View directory record Official record
Conditions
Obesity/Overweight
Interventions
ALT-801, Placebo
Drug · Other
Lead sponsor
Altimmune, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
391 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
31
States / cities
Birmingham, Alabama • Mesa, Arizona • Los Angeles, California + 25 more
Source: ClinicalTrials.gov public record
Updated Nov 28, 2023 · Synced Sep 24, 2026, 5:52 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

A Randomized Controlled Test of the Effects of CHI-554 on Fear.

NCT04577612
View directory record Official record
Conditions
Anxiety, Fear, Panic
Interventions
CHI-554
Drug
Lead sponsor
Canopy Growth Corporation
Industry
Eligibility
18 Years to 55 Years
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Fayetteville, Arkansas
Source: ClinicalTrials.gov public record
Updated Jun 2, 2021 · Synced Sep 24, 2026, 5:52 PM EDT
Withdrawn Phase 2 Interventional

A Study of JNJ-64304500 as Add-on Therapy in Participants With Active Crohn's Disease

NCT04655807
View directory record Official record
Conditions
Crohn Disease
Interventions
JNJ-64304500, Placebo, Adalimumab, Ustekinumab
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Evansville, Indiana
Source: ClinicalTrials.gov public record
Updated Apr 26, 2025 · Synced Sep 24, 2026, 5:52 PM EDT
Terminated Early Phase 1 Interventional Results available

Topical Timolol 0.5% Solution for Proliferating Infantile Hemangiomas

NCT01147601
View directory record Official record
Conditions
Hemangioma, Infant
Interventions
topical 0.5% Timolol, Control (placebo) group
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
1 Month to 8 Months
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jul 4, 2017 · Synced Sep 24, 2026, 5:52 PM EDT
Completed Phase 2 Interventional Results available

Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of ACT-128800 in Patients With Relapsing-remitting Multiple Sclerosis

NCT01006265
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
ACT-128800 Dose 1, Placebo, ACT-128800 Dose 2, ACT-128800 Dose 3
Drug
Lead sponsor
Actelion
Industry
Eligibility
18 Years to 55 Years
Enrollment
464 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
25
States / cities
Scottsdale, Arizona • Tucson, Arizona • Sacramento, California + 22 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2025 · Synced Sep 24, 2026, 5:52 PM EDT
Recruiting Phase 2Phase 3 Interventional

Optimizing Reperfusion to Improve Outcomes and Neurologic Function

NCT06990867
View directory record Official record
Conditions
Acute Ischemic Stroke
Interventions
JX10, Placebo
Drug
Lead sponsor
Corxel Pharmaceuticals
Industry
Eligibility
18 Years to 90 Years
Enrollment
740 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
20
States / cities
Long Beach, California • Los Angeles, California • Sacramento, California + 17 more
Source: ClinicalTrials.gov public record
Updated Sep 20, 2026 · Synced Sep 24, 2026, 5:52 PM EDT
Active, not recruiting Phase 2 Interventional

A Study of Nipocalimab in Participants With Active Idiopathic Inflammatory Myopathies

NCT05379634
View directory record Official record
Conditions
Myositis
Interventions
Nipocalimab, Placebo, Glucocorticoids
Drug · Other
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
19
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Beverly Hills, California + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 20, 2026 · Synced Sep 24, 2026, 5:52 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Vitamin K and Glucose Metabolism in Adults at Risk for Diabetes (Vita-K 'n' Adults Study)

NCT02366481
View directory record Official record
Conditions
Obesity, Insulin Resistance, Insulin Sensitivity, Beta-Cell Dysfunction, Prediabetes
Interventions
Placebo, Low-Dose Vitamin K2 Supplement (menaquinone-7; 90-mcg/d), High-Dose Vitamin K2 Supplement (menaquinone-7; 180-mcg/d)
Dietary Supplement
Lead sponsor
Augusta University
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2020
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 19, 2019 · Synced Sep 24, 2026, 5:52 PM EDT
Completed Phase 4 Interventional

Effect of Combination Therapy With Two Drugs (Colesevelam and Ezetimibe) in Patients With High Cholesterol

NCT00185107
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
Colesevelam Hydrochloride, Ezetimibe, Simvastatin
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years to 80 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005
U.S. locations
7
States / cities
San Diego, California • Ocala, Florida • Overland Park, Kansas + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2007 · Synced Sep 24, 2026, 5:52 PM EDT
Completed Phase 3 Interventional Results available

Study of Aripiprazole in the Treatment of Children and Adolescents With Autistic Disorder (AD)

NCT00337571
View directory record Official record
Conditions
Behavioral Symptoms, Autistic Disorder
Interventions
Aripiprazole, Placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
6 Years to 17 Years
Enrollment
218 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
31
States / cities
Birmingham, Alabama • Dothan, Alabama • Phoenix, Arizona + 28 more
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Sep 24, 2026, 5:52 PM EDT
Not listed Phase 3 Interventional

Acupuncture for the Treatment of Chronic Post-Chemotherapy Fatigue

NCT00658034
View directory record Official record
Conditions
Fatigue
Interventions
Acupuncture, Placebo Acupuncture
Procedure
Lead sponsor
Alta Bates Summit Medical Center
Other
Eligibility
18 Years to 64 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Berkeley, California
Source: ClinicalTrials.gov public record
Updated Oct 25, 2011 · Synced Sep 24, 2026, 5:52 PM EDT
Active, not recruiting Not applicable Interventional

Mindfulness And Placebo for Pain (MAPP) Study

NCT06720909
View directory record Official record
Conditions
Chronic Pain
Interventions
Mindfulness-Based Stress Reduction (MBSR), Open-Label Placebo (OLP), MBSR+OLP
Behavioral · Other
Lead sponsor
Arizona State University
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Sep 24, 2026, 5:52 PM EDT
Completed Phase 3 Interventional Results available

Effect of Nitric Oxide in Cardiac Surgery Patients With Endothelial Dysfunction.

NCT02836899
View directory record Official record
Conditions
Acute Kidney Injury
Interventions
Nitric Oxide, Placebo
Drug · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 9, 2026 · Synced Sep 24, 2026, 5:52 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Evaluation of TTP399 in Patients With Type 1 Diabetes

NCT03335371
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
TTP399, Placebo Oral Tablet
Drug
Lead sponsor
vTv Therapeutics
Industry
Eligibility
18 Years to 70 Years
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
15
States / cities
Beverly Hills, California • Escondido, California • Aurora, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2023 · Synced Sep 24, 2026, 5:52 PM EDT
Completed Phase 3 Interventional Results available

Pediatric Study in Children and Adolescents With Severe Plaque Psoriasis

NCT02471144
View directory record Official record
Conditions
Chronic Severe Plaque-type Psoriasis
Interventions
Experimental : Secukinumab low dose, Experimental: Secukinumab high dose, Placebo Comparator: Secukinumab Placebo, Active Comparator: Etanercept
Biological
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
6 Years to 17 Years
Enrollment
162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 10, 2023 · Synced Sep 24, 2026, 5:52 PM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate the Effect of Ranolazine and Dronedarone When Given Alone and in Combination in Patients With Paroxysmal Atrial Fibrillation

NCT01522651
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Ranolazine, Dronedarone, Ranolazine placebo, Dronedarone placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
15
States / cities
Beverly Hills, California • Newport Beach, California • San Francisco, California + 12 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2020 · Synced Sep 24, 2026, 5:52 PM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety of Bumetanide Oral Liquid Formulation in Children Aged From 2 to Less Than 7 Years Old With Autism Spectrum Disorder.

NCT03715153
View directory record Official record
Conditions
Autism Spectrum Disorder (ASD)
Interventions
BUMETANIDE (S95008) for week 0 - 26, PLACEBO for week 0 - 26, Open-Label BUMETANIDE (S95008) for weeks 26 - 52
Drug
Lead sponsor
Institut de Recherches Internationales Servier
Other
Eligibility
2 Years to 6 Years
Enrollment
211 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Staten Island, New York
Source: ClinicalTrials.gov public record
Updated Jun 4, 2023 · Synced Sep 24, 2026, 5:52 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Clinical Study to Evaluate the Efficacy of VR506 Using a New Inhaler for the Treatment of Asthma

NCT01472757
View directory record Official record
Conditions
Asthma
Interventions
VR506, Placebo
Drug
Lead sponsor
Vectura Limited
Industry
Eligibility
12 Years to 65 Years
Enrollment
374 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
32
States / cities
Fountain Valley, California • Los Angeles, California • Mission Viejo, California + 28 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2020 · Synced Sep 24, 2026, 5:52 PM EDT
Recruiting Phase 3 Interventional

eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 Inflammation

NCT07177339
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Depemokimab, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years to 75 Years
Enrollment
1,196 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
42
States / cities
Newport Beach, California • Lakewood, Colorado • Brandon, Florida + 35 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Sep 24, 2026, 5:52 PM EDT
Completed Not applicable Interventional

Harnessing Placebo Effects in Methadone Treatment

NCT02941809
View directory record Official record
Conditions
Opioid-use Disorder, Opioid-Related Disorders
Interventions
Open-Label Placebo (OLP)
Behavioral
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 10, 2020 · Synced Sep 24, 2026, 5:52 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Thorough QT Study to Evaluate Ampreloxetine in Healthy Subjects

NCT04688632
View directory record Official record
Conditions
Symptomatic Neurogenic Orthostatic Hypertension, nOH
Interventions
Ampreloxetine <Dose A>, Ampreloxetine <Dose B>, Ampreloxetine Placebo, Moxifloxacin, Moxifloxacin Placebo
Drug
Lead sponsor
Theravance Biopharma
Industry
Eligibility
18 Years to 55 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Apr 19, 2021 · Synced Sep 24, 2026, 5:52 PM EDT